Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells

A number of prostate cancer (PCa)‐specific genomic aberrations (denominated BRCAness genes) have been discovered implicating sensitivity to PARP inhibition within the concept of synthetic lethality. Recent clinical studies show favorable results for the PARP inhibitor olaparib used as single agent f...

Descripción completa

Detalles Bibliográficos
Autores principales: Feiersinger, Gertrud E., Trattnig, Kristina, Leitner, Peter D., Guggenberger, Fabian, Oberhuber, Alexander, Peer, Sarah, Hermann, Martin, Skvortsova, Ira, Vrbkova, Jana, Bouchal, Jan, Culig, Zoran, Santer, Frédéric R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891051/
https://www.ncbi.nlm.nih.gov/pubmed/29465803
http://dx.doi.org/10.1002/1878-0261.12185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891051/
https://www.ncbi.nlm.nih.gov/pubmed/29465803
http://dx.doi.org/10.1002/1878-0261.12185

Ejemplares similares